| Abstract P088 – Table 1. Summary of participant characteristics at time of switch, outcomes through week 240. | ||
|---|---|---|
| Study 1489 | Study 1490 | |
| DTG/ABC/3TC to B/F/TAF (n=254) | DTG+F/TAF to B/F/TAF (n=265) | |
| Participant characteristics at time of switcha | ||
| Median age (Q1, Q3) | 36 (30, 45) | 38 (30, 48) |
| Female sex at birth | 11% | 10% |
| Black or African descent | 37% | 30% |
| Latinx/Hispanic | 21% | 28% |
| CD4 count, median, cells/mm3 (Q1, Q3) | 766 (599, 1023) | 730 (550, 958) |
| eGFRCG, median, mL/min (Q1, Q3) | 115.6 (98.5, 137.6) | 111.0 (95.1, 134.8) |
| Body weight, median, kg (Q1, Q3) | 83.0 (72.6, 94.3) | 81.7 (71.0, 96.0) |
| Efficacy and safety, W240 | ||
| Median duration of exposure to B/F/TAF, W (Q1, Q3) | 96 (95.7, 96.3) | 96 (95.9, 96.4) |
| HIV‐1 RNA <50 c/mL (n/N), [Missing=Excluded] | 99.5% (217/218) | 99.1% (232/234) |
| HIV‐1 RNA < 50 c/mL (n/N), [Missing=Failure] | 85.4% (217/254) | 87.5% (232/265) |
| CD4 count, median changeb, cells/mm3 (Q1, Q3) | ‐6 (‐116, 82) | 3 (‐91, 110) |
| eGFRCG, median changeb, mL/min (Q1, Q3) | 2.0 (‐7.2, 12.7) | 1.3 (‐7.3, 11.1) |
| Body weight, median changeb, kg (Q1, Q3) | 2.4 (‐0.4, 5.6) | 1.3 (‐1.9, 5.0) |
| Fasting lipids, mmol/L, median (time of B/F/TAF start → OLE wk 96) | ||
| Total cholesterol | 4.27 → 4.53 | 4.42 → 4.50 |
| LDL | 2.90 → 2.97 | 3.08 → 3.03 |
| HDL | 1.24 → 1.24 | 1.22 → 1.22 |
| Triglycerides | 1.08 → 1.11 | 1.12 → 1.20 |
| Total cholesterol: HDL ratio | 3.3 → 3.5 | 3.5 → 3.7 |
aDefined as the last non‐missing value obtained on or prior to the first dose of open‐label B/F/TAF;
bfrom time of B/F/TAF start. Prior to B/F/TAF, all participants completed 144 weeks of blinded DTG/ABC/3TC or DTG+FTC/TAF.